SHARES:ML proves that bio is still a buy

Back to that perennially intriguing stock market chestnut: ML Laboratories, and its future prospects. At a market capitalisation of pounds 370.5m, clearly great things are expected - given that sales are currently running at a little over pounds 5m a year. However, many now believe the last year has seen all the ingredients put in place for a successful future. Its kidney dialysis fluid, Icodial, has been signed to world leader Baxter, while it has sold European distribution rights for a dry powder asthma inhaler to Medeva. No doubt, there is still some risk, with future income still something of a mystery. That said, the shares, at 275p have fallen substantially in recent months, in line with the shake-up in the biotech sector. Given that ML is well ahead of the pack, in terms of getting its products to market, the shares look better value than for some time. A tentative buy.

The food sector has hardly been the place to have your money invested over the last year - as one wag pointed out, it's not so much a case of picking the winners, as avoiding the losers. Perkins Food at least shows some faith in its future prospects, with a 1-for-6 rights issue for pounds 15.5m, to buy the Dutch Disselkoen Group. The attraction to Perkins is that the business, one of the largest fresh food exporters from the Netherlands, gives it instant access to Germany, including a toehold in the country's supermarket chains. With European borders disappearing, the deal should shore up the group's competitive position, while it can also sell its own fresh produce into Disselkoen. Although the Dutch group's margins are, like most fresh-produce suppliers', razor thin, the deal should be earnings neutral in 1997. While the shares, at 81.5p, are making a gradual recovery from the setbacks of 1992, now seems the time for a more whole- hearted commitment. Buy.

More food. If Perkins has yet to fully regain the confidence of investors, that old warhorse Associated British Foods (417p), continues to keep pace with the market. While the business rarely dazzles, nor does it let down shareholders. Tomorrow, it posts its final figures for 1996. Operating profit should come in at around pounds 378m, a gain of 13 per cent, with sales of pounds 5.64bn, up 15 per cent. The shares remain a buy.

A company that is listed over there - on Nasdaq, to be precise - is obtaining a listing over here. Through a placing on the London Stock Exchange, Xenova Group, the UK-based biotech company that develops drugs from natural micro-organisms, hopes to raise pounds 25m. Its first product should be ready for market by 2000. The XR5000 anti-cancer drug should enter clinical trials early next year. Other products include XR9051, to overcome multidrug resistance in cancer chemotherapy, with up to a pounds 1.4bn market. It also has tie-ins to Genentech, Genzyme and Warner-Lambert. Listing details will be published later this month, but the company has some exciting products, and could be worth following.

Tough times at car dealer Evans Halshaw, which announced it was closing a fifth of its dealerships, and taking a pounds 19.8m restructuring charge. To add to its woes, the group said August and September had been difficult for trading, with a consequent impact on full-year results. Although the shares were off only 5.5p, to 248.5p, the prospects are mixed. While the intention is to improve the return on capital, clearly the business is lagging behind its competitors, who have stolen a lead on it in many areas. EH professes it wants to build up its presence "in the larger conurbations, like Birmingham, Leicester and Sheffield". But there, of course, is where the competition is fiercest - although volumes, for successful sites, are far higher. That said, the final impact on full-year results could even be neutral, given the benefit of margin enhancement from the restructuring. Nevertheless, there are better value shares elsewhere in the sector. Sell.

Suggested Topics
Start your day with The Independent, sign up for daily news emails
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

SThree: HR Benefits Manager

£40000 - £50000 per annum + pro rata: SThree: SThree Group have been well esta...

Recruitment Genius: Office Manager / Financial Services

£30000 - £37000 per annum: Recruitment Genius: Established in 1999, a highly r...

Jemma Gent: Year End Accountant

£250-£300 Day Rate: Jemma Gent: Are you a qualified accountant with strong exp...

Jemma Gent: Management Accountant

£230 - £260 Day Rate: Jemma Gent: Do you want to stamp your footprint in histo...

Day In a Page

War with Isis: Fears that the looming battle for Mosul will unleash 'a million refugees'

The battle for Mosul will unleash 'a million refugees'

Aid agencies prepare for vast exodus following planned Iraqi offensive against the Isis-held city, reports Patrick Cockburn
Yvette Cooper: We can't lose the election. There's too much on the line

Yvette Cooper: We can't lose the election. There's too much on the line

The shadow Home Secretary on fighting radical Islam, protecting children, and why anyone in Labour who's thinking beyond May must 'sort themselves out'
A bad week for the Greens: Leader Natalie Bennett's 'car crash' radio interview is followed by Brighton council's failure to set a budget due to infighting

It's not easy being Green

After a bad week in which its leader had a public meltdown and its only city council couldn't agree on a budget vote, what next for the alternative party? It's over to Caroline Lucas to find out
Gorillas nearly missed: BBC producers didn't want to broadcast Sir David Attenborough's famed Rwandan encounter

Gorillas nearly missed

BBC producers didn't want to broadcast Sir David Attenborough's famed Rwandan encounter
Downton Abbey effect sees impoverished Italian nobles inspired to open their doors to paying guests for up to €650 a night

The Downton Abbey effect

Impoverished Italian nobles are opening their doors to paying guests, inspired by the TV drama
China's wild panda numbers have increased by 17% since 2003, new census reveals

China's wild panda numbers on the up

New census reveals 17% since 2003
Barbara Woodward: Britain's first female ambassador to China intends to forge strong links with the growing economic superpower

Our woman in Beijing builds a new relationship

Britain's first female ambassador to China intends to forge strong links with growing economic power
Courage is rare. True humility is even rarer. But the only British soldier to be awarded the Victoria Cross in Afghanistan has both

Courage is rare. True humility is even rarer

Beware of imitations, but the words of the soldier awarded the Victoria Cross were the real thing, says DJ Taylor
Alexander McQueen: The catwalk was a stage for the designer's astonishing and troubling vision

Alexander McQueen's astonishing vision

Ahead of a major retrospective, Alexander Fury talks to the collaborators who helped create the late designer's notorious spectacle
New BBC series savours half a century of food in Britain, from Vesta curries to nouvelle cuisine

Dinner through the decades

A new BBC series challenged Brandon Robshaw and his family to eat their way from the 1950s to the 1990s
Philippa Perry interview: The psychotherapist on McDonald's, fancy specs and meeting Grayson Perry on an evening course

Philippa Perry interview

The psychotherapist on McDonald's, fancy specs and meeting Grayson Perry on an evening course
Bill Granger recipes: Our chef recreates the exoticism of the Indonesian stir-fry

Bill Granger's Indonesian stir-fry recipes

Our chef was inspired by the south-east Asian cuisine he encountered as a teenager
Chelsea vs Tottenham: Harry Kane was at Wembley to see Spurs beat the Blues and win the Capital One Cup - now he's their great hope

Harry Kane interview

The striker was at Wembley to see Spurs beat the Blues and win the Capital One Cup - now he's their great hope
The Last Word: For the good of the game: why on earth don’t we leave Fifa?

Michael Calvin's Last Word

For the good of the game: why on earth don’t we leave Fifa?
HIV pill: Scientists hail discovery of 'game-changer' that cuts the risk of infection among gay men by 86%

Scientists hail daily pill that protects against HIV infection

Breakthrough in battle against global scourge – but will the NHS pay for it?